Article Source: Nature Biotechnology

Original Title: Chinese health biotech and the billion-patient market

Online Archive:https://www.nature.com/articles/nbt0108-37

Editor’s Note：Nature Biotechnology published the article “Chinese Health Biotech and the Billion-Patient Market,” offering an in-depth analysis of China’s vast patient population alongside its rapidly emerging healthcare biotechnology and biopharmaceutical industry. The article highlights that while strong government support and the return of overseas-trained entrepreneurs (“sea turtles”) have been key drivers of innovation, the lack of clear exit mechanisms for investors remains a significant bottleneck constraining industrialization and long-term sector growth.

Within this broader context, Shenzhen Chipscreen Biosciences is featured as a representative case study of China’s most innovative domestic biotech companies. Founded in 2001 by returnees with scientific and industrial experience in the United States, Chipscreen has developed a dual business model: the discovery and development of proprietary innovative drug candidates, and the provision of comprehensive research services spanning target identification to clinical evaluation.

The company has built an extensive and globally relevant pipeline targeting major diseases such as type 2 diabetes, lung cancer, colon cancer, metabolic syndrome, and cardiovascular diseases. Its leading compounds, including chiglitazar and chidamide, have advanced into clinical development, supported by a strong intellectual property portfolio with multiple US and international patents.

Chipscreen is also recognized for its proprietary chemical genomics–based drug discovery platform, which supports both internal innovation and external collaborations. The company has established strategic international partnerships, including co-development of chidamide with US-based HUYA Biosciences and research collaborations with Roche, leveraging high-throughput screening and advanced discovery technologies.

The article emphasizes that Chipscreen’s management team has effectively utilized its international experience to integrate global resources, enabling the company to build both innovative drug pipelines and service capabilities. This dual strategy positions Chipscreen as a significant and competitive global player in the field of novel drug discovery and development.

For more details, please click here。